- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01371799
A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers (MAA113746)
12 juni 2017 bijgewerkt door: GlaxoSmithKline
A Double Blind, Randomized, Placebo Controlled, Cross-over Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers
This will be a double blind, randomised, placebo controlled, cross over study in which up to 20 otherwise healthy male nicotine abstinent smokers will be tested following 3 acute treatment conditions (placebo, 4 and 8mg of GSK1034702).
Each subject will undergo screening assessments within 30 days prior to administration of the first dose of study medication.
There will be 3 treatment sessions and dosing will be separated by a minimum 1 week washout period.
There will be two testing days (day 1 and day 2) per treatment session.
On each treatment session subjects will be admitted on day 1.
On day 1, subjects will be administered placebo and approximately 3 hours later, there will be a Baseline EEG/ERP recording, neuropsychological (Cogstate battery) testing and mood/craving/dependence questionnaire assessments .
Subjects will be allowed to smoke until approximately midnight on day 1.
On day 2, subjects will undergo a pre-drug neuropsychological (Cogstate battery) testing and questionnaire assessments of mood/craving.
This will be conducted approximately 1 hour prior to dosing.
Subjects will be randomized to one of six treatment sequences.
Post dose EEG/ERP recording, neuropsychological (Cogstate battery) testing and mood/craving measurements will be conducted between 3 and 6 hours post treatment to coincide with peak pharmacokinetic effects.
This testing will be performed approximately at 12pm following at least 12hrs of nicotine abstinence.
Blood samples will be collected at baseline (pre-drug) and following drug administration to quantify exposure levels.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
9
Fase
- Fase 1
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Cambridge, Verenigd Koninkrijk, CB2 2GG
- GSK Investigational Site
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 55 jaar (Volwassen)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Mannelijk
Beschrijving
Inclusion Criteria A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- Otherwise healthy smokers as determined by a responsible physician, based on a medical evaluation including own and familial medical history, physical examination, psychiatric history, psychiatric evaluation, laboratory tests and cardiac monitoring.
- A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Subjects must have QTc values within the normal range, i.e. QTcB or QTcF < 450 msec. The following normal ranges for blood pressure and heart rate are given as a guide: Systolic blood pressure ≥90 and ≤140 mmHg Diastolic blood pressure ≥60 and ≤90 mmHg Heart rate ≥50 and ≤90 bpm - Male subjects between 18 and 55 years of age.
- Male subjects must agree to use one of the contraception methods listed in Section 8.1.1. This criterion must be followed from the time of the first dose of study medication until 3 months post-last dose.
- Subject is a smoker, i.e. on average smokes 10 or more cigarettes per day for at least 1 year prior to the screening visit. Urinary cotinine levels indicative of smoking at screening.
- Body weight > 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive).
- Subjects must have AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). Tests may be repeated once but must be within the above limits by the day one visit.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion Criteria
- A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Current or past diagnosis of psychiatric disorder, as assessed by the MINI.
- Subjects, who in the investigator's judgement, pose a significant suicide risk. Evidence of serious suicide risk may include any history of suicidal behavior and/or any suicidal ideation of type 4 or 5 on the C-SSRS in the last 6 months.
- Current or past diagnosis of cardiovascular disease including but not limited to hypertension, cardiac arrhythmias, personal or family history of long QT syndrome, cardiac conduction disorder and/or risk factors for coronary artery disease (i.e. family history in more than 2 first degree relatives) or other clinically significant cardiac disease
- Current or past diagnosis of cerebrovascular disease (e.g., stroke, transient ischemic attacks, aneurysms).
- Current or past diagnosis of autonomic dysfunction (e.g. prone to fainting, orthostatic hypotension). Current or past diagnosis of acute or chronic respiratory disease (excluding childhood asthma and allergic rhinitis) and/or abnormal spirometry for age, sex and height at screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Subjects with a history of gastrointestinal bleeding and/or a history of peptic ulcer disease and/or presence of active gastrointestinal disease.
- Subjects with an unstable medical disorder or a disorder (including surgical interventions) that would likely interfere with the action, absorption, distribution, metabolism or excretion of GSK1034702, may pose a safety concern, or interfere with accurate assessment of safety.
- History of regular alcohol consumption within 6 months of the study defined as: For males: an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units. One unit is equivalent to a half-pint (220 mL) of beer or 1 (125 mL) measure of spirits or 1 glass (125 mL) of wine.
- A positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- A positive test for HIV antibody.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort and Gingko biloba) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice (and exotic citrus fruits, grapefruit hybrids or fruit juices) from 7 days prior to the first dose of study medication.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.
- Unwillingness or inability to follow the procedures outlined in the protocol
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Placebo-vergelijker: Placebo
|
Placebo
4mg and 8mg Study drug
|
Experimenteel: Study drug at 4mg
GSK1034702 at 4mg
|
Placebo
4mg and 8mg Study drug
|
Experimenteel: Study drug at 8mg
GSK1034702 at 8mg
|
Placebo
4mg and 8mg Study drug
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Measures will include changes in cognition measures of specific biomarkers
Tijdsspanne: 12 months
|
To investigate the effects of GSK1034702 on the mismatch negativity neurophysiologic marker of cognition.
|
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Measures will include changes in the neurophysiologic markers of cognition
Tijdsspanne: 12 Months
|
To investigate the effects of GSK1034702 on other neurophysiologic markers of cognition including, P50 suppression, P300, PPI and synchronized oscillations.
|
12 Months
|
Measures of changes in cognition biomarkers vs. the stduy drug
Tijdsspanne: 12 months
|
To investigate the relationship between changes in the above neurophysiologic markers of cognitive function and drug exposure
|
12 months
|
Measures of cogstate tests of attention in tests mentioned To investigate the effects of GSK1034702 on Cogstate neuropsychologic tests of attention, working memory, learning and executive function
Tijdsspanne: 12 months
|
To investigate the effects of GSK1034702 on Cogstate neuropsychologic tests of attention, working memory, learning and executive function
|
12 months
|
Measures of difference between the tests in cogstate and the drug levels at different concentrations To investigate the relationship between changes in Cogstate behavioural task performance and drug exposure
Tijdsspanne: 12 months
|
To investigate the relationship between changes in Cogstate behavioural task performance and drug exposure
|
12 months
|
Safety measures and PK parameters and PK parameters will be measures, Vital signs, BP. To obtain further safety and PK information following oral administration of GSK1034702 to healthy subjects
Tijdsspanne: 12 months
|
To obtain further safety and PK information following oral administration of GSK1034702 to healthy subjects
|
12 months
|
Measures in modd/craving To investigate changes in mood/craving in the nicotine "on" state (baseline), following nicotine abstinence and following treatment
Tijdsspanne: 12 months
|
To investigate changes in mood/craving in the nicotine "on" state (baseline), following nicotine abstinence and following treatment
|
12 months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- te Beek ET, Hay JL, Bullman JN, Burgess C, Nahon KJ, Klaassen ES, Gray FA, van Gerven JM. Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers. Br J Clin Pharmacol. 2013 May;75(5):1328-39. doi: 10.1111/bcp.12004.
- Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, Swirski B, Lawrence P, Bentley GD, O'Neill BV, Robertson J, Watson S, Jones GA, Maruff P, Croft RJ, Laruelle M, Bullmore ET. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol. 2013 May;16(4):721-31. doi: 10.1017/S1461145712000752. Epub 2012 Aug 29.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
17 december 2009
Primaire voltooiing (Werkelijk)
18 juni 2010
Studie voltooiing (Werkelijk)
18 juni 2010
Studieregistratiedata
Eerst ingediend
14 april 2011
Eerst ingediend dat voldeed aan de QC-criteria
9 juni 2011
Eerst geplaatst (Schatting)
13 juni 2011
Updates van studierecords
Laatste update geplaatst (Werkelijk)
14 juni 2017
Laatste update ingediend die voldeed aan QC-criteria
12 juni 2017
Laatst geverifieerd
1 juni 2017
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 113746
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
JA
Beschrijving IPD-plan
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Bestudeer gegevens/documenten
-
Gegevensset individuele deelnemers
Informatie-ID: 113746Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Specificatie gegevensset
Informatie-ID: 113746Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisch analyseplan
Informatie-ID: 113746Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulier geïnformeerde toestemming
Informatie-ID: 113746Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Leerprotocool
Informatie-ID: 113746Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisch onderzoeksrapport
Informatie-ID: 113746Informatie opmerkingen: For additional information about this study please refer to the GSK Clinical Study Register
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Psychische aandoening
-
University of HoustonOnbekend
-
South West Yorkshire Partnership NHS Foundation...OnbekendRedenen voor detentie op grond van de Mental Health Act 1983Verenigd Koninkrijk
-
Yonsei UniversityVoltooidVerpleegkundigen die werken bij het Community Mental Health Welfare CenterKorea, republiek van
-
New York City Health and Hospitals CorporationBeëindigdGlaucoom | Ziekte van het netvlies | Visuele Pathway DisorderVerenigde Staten
-
Neuro-Eye Diagnostic Systems, LLCNeuro-ophthalmology of Texas PLLCAanmelden op uitnodigingMacula ziekte | Visuele Pathway Disorder | Ziekte van de oogzenuwVerenigde Staten
-
Fondazione G.B. Bietti, IRCCSVoltooidGlaucoom | Optische neuropathie, ischemische | Optische zenuw | Visuele Pathway Disorder | Neurale geleidingItalië
-
University of MiamiNational Eye Institute (NEI)VoltooidGlaucoom | Maculaire degeneratie | Retinale degeneratie | Optische neuropathie | DrDeramus verdachte | Visuele Pathway DisorderVerenigde Staten
-
Isfahan University of Medical SciencesVoltooidZiekte van Tanger | Body Mass Index Quantitative Trait Locus 5 DisorderIran, Islamitische Republiek
-
Weill Medical College of Cornell UniversityUniversity of California, Los Angeles; University of Wisconsin, MilwaukeeVoltooidTourette syndroom | De stoornis van Gilles de la Tourette | Gilles de la Tourette | Gilles de la Tourette-syndroom | Ziekte van Gilles de la Tourette | Tourette-ziekte | Tic Disorder, Gecombineerde Vocale en Multiple Motor | Meerdere motorische en vocale ticstoornis, gecombineerd | Ziekte van Gilles... en andere voorwaarden
Klinische onderzoeken op Drug
-
University of ZurichVoltooid
-
Malahat AmaniVoltooidPatiëntacceptatie van gezondheidszorgIran, Islamitische Republiek
-
Chinese PLA General HospitalOnbekendDiffuse laesies van de kransslagader
-
University Hospital UlmWervingChronische totale occlusie | Chronische totale occlusie van kransslagaderDuitsland
-
Medical University of South CarolinaWayne State University; National Institute on Minority Health and Health Disparities... en andere medewerkersVoltooidDrugsmisbruikVerenigde Staten
-
Academisch Medisch Centrum - Universiteit van Amsterdam...WervingCoronaire hartziekteNederland
-
Cardiocentro TicinoUniversity of BernWervingChronisch Coronair SyndroomZwitserland
-
Nanjing First Hospital, Nanjing Medical UniversityWervingCoronaire hartziekteChina
-
GIE MedicalActief, niet wervendBiliaire ziekte | Biliaire vernauwing | Biliaire obstructie | Biliaire anastomose stenoseParaguay
-
Shanghai MicroPort Medical (Group) Co., Ltd.Werving